CMPS — COMPASS Pathways Plc - American

Is CMPS overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Medical Care Facilities

Oversold As of November 17, 2026

COMPASS Pathways Plc - American (CMPS) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Medical Care Facilities) last closed at $8.27. The rating moved from Neutral to Oversold on November 16, 2026.

See all oversold Healthcare stocks →

AI analysis

COMPASS Pathways is a clinical-stage company with a differentiated psilocybin therapy for treatment-resistant depression; its valuation is driven primarily by upcoming trial milestones, regulatory clarity and partnership prospects. The investment case balances a sizable addressable market and high-impact upside from successful readouts against substantial execution and financing risk. Near-term movement is likely to be driven by clinical newsflow and funding activity; longer-term outcomes depend on regulatory acceptance, payer coverage and potential strategic alliances.

Key factors

  • Clinical-stage lead asset (COMP360) addressing treatment-resistant depression with differentiated psilocybin formulation and established Phase II/III program
  • Binary, high-impact clinical readouts and regulatory pathway that can drive large moves in valuation
  • Strategic partnerships and licensing potential with larger pharma could de-risk commercialization and provide non-dilutive funding
  • Broad unmet need in mental health and growing institutional/payer interest in novel therapeutics underpin long-term addressable market
  • Current market tone is cautiously risk-on, which can support speculative biotech flows in the near term
  • Operational sensitivity to cash runway and sequencing of trial milestones; financing events likely to affect share price

Risks

  • Clinical trial failure or delayed readouts for lead programs, which would materially reduce valuation
  • Regulatory uncertainty for psychedelics-based therapies, including potential restrictive labeling or additional data requirements
  • Limited cash runway and the likelihood of equity raises that can dilute existing shareholders
  • Reimbursement and payer acceptance risk for a novel therapeutic class could constrain commercial uptake
  • Competitive entrants and alternative therapeutic approaches in psychiatric disorders may limit market share
  • Stigma, public perception and policy/regulatory shifts around psychedelic treatments could increase volatility

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for CMPS — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.